Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections Overview | 10 | 1 |
| Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections Comparative Analysis | 11 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Therapeutics under Development by Companies | 12 | 2 |
| Vancomycin-Resistant Enterococcus faecium Infections Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Pipeline Products Glance | 15 | 2 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Products under Development by Companies | 17 | 2 |
| Vancomycin-Resistant Enterococcus faecium Infections Products under Investigation by Universities/Institutes | 19 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Companies Involved in Therapeutics Development | 20 | 18 |
| Alchemia Limited | 20 | 1 |
| Alvogen Korea Co., Ltd. | 21 | 1 |
| Aphios Corporation | 22 | 1 |
| C3 Jian, Inc | 23 | 1 |
| Cellceutix Corporation | 24 | 1 |
| Helix BioMedix, Inc. | 25 | 1 |
| Hsiri Therapeutics LLC | 26 | 1 |
| LegoChem Biosciences, Inc | 27 | 1 |
| Lytix Biopharma AS | 28 | 1 |
| MGB Biopharma Limited | 29 | 1 |
| MicuRx Pharmaceuticals, Inc. | 30 | 1 |
| Nanotherapeutics, Inc. | 31 | 1 |
| NovoBiotic Pharmaceuticals, LLC | 32 | 1 |
| Oragenics, Inc. | 33 | 1 |
| Sealife PHARMA GMBH | 34 | 1 |
| Sentinella Pharmaceuticals, Inc. | 35 | 1 |
| TAXIS Pharmaceuticals, Inc. | 36 | 1 |
| Wockhardt Limited | 37 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Assessment | 38 | 9 |
| Assessment by Monotherapy Products | 38 | 1 |
| Assessment by Target | 39 | 2 |
| Assessment by Mechanism of Action | 41 | 2 |
| Assessment by Route of Administration | 43 | 2 |
| Assessment by Molecule Type | 45 | 2 |
| Drug Profiles | 47 | 48 |
| AM-218 Drug Profile | 47 | 1 |
| BDM-I Drug Profile | 48 | 2 |
| brilacidin tetrahydrochloride Drug Profile | 50 | 10 |
| chrysophaentin Drug Profile | 60 | 1 |
| closthioamide Drug Profile | 61 | 1 |
| Epimerox Drug Profile | 62 | 1 |
| HB-1345 Drug Profile | 63 | 1 |
| HT-01 Drug Profile | 64 | 1 |
| HT-02 Drug Profile | 65 | 1 |
| IBN-1 Drug Profile | 66 | 1 |
| LCB-010371 Drug Profile | 67 | 2 |
| LCB-010699 Drug Profile | 69 | 1 |
| LTX-109 Drug Profile | 70 | 2 |
| Marinus Drug Profile | 72 | 1 |
| MGBBP-3 Drug Profile | 73 | 2 |
| MRX-I Drug Profile | 75 | 2 |
| MRX-IV Drug Profile | 77 | 1 |
| NAI-107 Drug Profile | 78 | 1 |
| NAI-108 Drug Profile | 79 | 1 |
| NAI-603 Drug Profile | 80 | 1 |
| OG-253 Drug Profile | 81 | 2 |
| ramoplanin Drug Profile | 83 | 1 |
| SLP-0904 Drug Profile | 84 | 1 |
| SLP-0905 Drug Profile | 85 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 86 | 1 |
| Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections Drug Profile | 87 | 1 |
| Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections Drug Profile | 88 | 1 |
| Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections Drug Profile | 89 | 1 |
| SP-2078 Drug Profile | 90 | 1 |
| Synthetic Peptides for Vancomycin Resistant Enterococci Infections Drug Profile | 91 | 1 |
| Teixobactin Drug Profile | 92 | 2 |
| WCK-4086 Drug Profile | 94 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Dormant Projects | 95 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Discontinued Products | 96 | 1 |
| Vancomycin-Resistant Enterococcus faecium Infections Product Development Milestones | 97 | 3 |
| Featured News &Press Releases | 97 | 1 |
| Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I | 97 | 1 |
| Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project | 97 | 1 |
| Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 | 98 | 1 |
| May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent | 98 | 1 |
| Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I | 99 | 1 |
| Appendix | 100 | 2 |
| Methodology | 100 | 1 |
| Coverage | 100 | 1 |
| Secondary Research | 100 | 1 |
| Primary Research | 100 | 1 |
| Expert Panel Validation | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |